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Placental transfer of lactate, glucose and 2-deoxyglu-
cose was examined employing the in situ perfused
placenta. Control and streptozotocin induced diabet-
ic Wistar rats were infused with [U-14C]-glucose and
[3H]-2-deoxyglucose (2DG). The fetal side of the pla-
centa was perfused with a cell free medium and glu-
cose uptake was calculated in the adjacent fetuses.
Despite the 5-fold higher maternal plasma glucose
concentration in the diabetic dams the calculated
fetal glucose metabolic index was not significantly
different between the 2 groups. Placental blood flow
was reduced in the diabetic animals compared with
controls but reduction of transfer of [U-14C]-glucose
and [3H]-2-deoxyglucose and endogenously derived
[14C]-Lactate to the fetal compartment, could not be
accounted for by reduced placental blood flow
alone. There was no significant net production or
uptake of lactate into the perfusion medium that
had perfused the fetal side of the placenta in either
group. The plasma lactate levels in the fetuses adja-
cent to the perfused placenta were found to be high-
er than in the maternal plasma and significantly
higher in the fetuses of the diabetic group compared
with control group. In this model the in-situ per-
fused placenta does not secrete significant quanti-
ties of lactate into the fetal compartment in either
the control or diabetic group.
Keywords: Placental transport; Lactate; Glucose; Maternal
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INTRODUCTION
Lactate is a three carbon molecule derived from
anaerobic metabolism that occurs in most cells.
Classically lactate has been considered a product
of anaerobic glycolysis or a substrate for gluco-
neogenesis or glycogenesis in liver. Lactate also
has an important role in carbohydrate metabo-
lism by virtue of the rapid equilibrium that
exists between lactate and pyruvate, which
allows lactate to enter the citric acid cycle. It
therefore represents a major energy source.
Under aerobic conditions lactate levels within
tissues are usually low due to its rapid turnover
rates. [1-4] The exception being in normal mam-
malian pregnancies where lactate concentrations
are higher in fetal than in the maternal circulation,
in humans, [5,6] sheep, [7,8] guinea pigs [9] and
rats.[1] The elevated levels of this metabolite in
the fetal circulation were shown to originate from
the placenta in guinea-pigs using an in vitro pla-
cental preparation. [9] This has also been demon-
strated in sheep in in-vivo experiments at term, [7,81
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but not at midgestation. [111 This led to the
assumption that the elevated fetal plasma lactate
levels could be derived from placental anaerobic
glycolysis. In diabetic pregnancies fetal plasma
lactate concentrations have been reported to be
significantly elevated compared with those of
non-diabetic pregnancies. [12] Additionally placen-
tal glycogen stores are significantly increased [13]
compared with those of non-diabetic pregnancies.
Thus the higher fetal lactate concentration in the
presence of maternal diabetes may be of placental
origin, especially as fetal pO2 values of the umbili-
cal vessels from diabetic patients were reported to
be within the normal range. [12]
The aim of these studies was to determine
whether circulating maternal glucose could be
the source of lactate in the fetal circulation of
normal and diabetic pregnant rats. This was
achieved by examining the transfer of glucose
and lactate derived from glucose across the in-
situ perfused placenta. Fetal plasma concentra-
tions of glucose and lactate as well as tissue
glucose uptake were also estimated.
MATERIALS AND METHODS
Chemicals
[U-14C]-glucose, [3H]-2-deoxyglucose (2DG) and
Sodium 125Iodide were obtained from Amersham
International plc (Amersham, Bucks.). The anaes-
thetic Intraval Sodium was obtained from May
and Baker (Dagenham, Essex). Ion exchange
resinsAG 50W 8 (100-200 mesh, H+ form) and
AG 1 8 (100-200 mesh, acetate form) used in
the separation of lactate from glucose were
obtained from Bio-Rad Laboratories (Watford,
Herts.) and Optiphase HiSafe scintillant from
Wallac UK (Milton Keynes). Lactate dehydroge-
nase and nicotinamide adenine dinucleotide
(NAD +) were from Boehringer Mannheim
Biochemica (Lewes, Sussex). Dextran 40 was from
Pharmacia LKB Biotechnology (Milton Keynes)
and rat insulin standard used in the radioim-
munoassay from Nova Biolabs Ltd. (Basingstoke)
and the rabbit anti-guinea pig antibodies were
from Immunodiagnostics Ltd. (Tyne and Wear).
Streptozotocin, bovine serum albumin (Fraction
V), D-glucose, antipyrine, perchloric acid, formic
acid and all other chemicals used in the enzymatic
and radiometric assays were obtained from BDH
Chemicals Ltd. (Poole, Dorset) and were of ana-
lytical grade.
Animal Experimentation
Wistar rats (200-250g; B and K Universal Ltd.
Hull) were mated and day 0 of pregnancy was
designated as the day a vaginal plaque was
noted. On day 4, ten rats were made diabetic by
a single intra-peritoneal (i.p.) injection of strepto-
zotocin (40mg/kg). Rats were maintained on
standard breeding rat chow throughout ges-
tation. This diet consisted of 31.5% protein,
43.5% carbohydrate, 4.0% fats, 12.2% dietary fibre
and 2.5% supplementations (vitamins, minerals
and amino acids). On day 20 of gestation, rats
were anaesthetized with Intraval (i.p.) at a dose
of 70mg/kg for controls and 60mg/kg body
weight for diabetic rats. Once anaesthetized, the
rat was placed on a thermo-regulated heating
pad where the rat body temperature was main-
tained at 38C by feedback from a rectal probe.
Cannulation of Maternal Vessels
Experimentation procedures carried out on the
rats were previously described. [14] In brief, the
left maternal external jugular vein was cannulat-
ed to enable the infusion of radioactive cocktail
and antipyrine in saline. The right carotid artery
was cannulated for maternal blood sampling
and the monitoring of blood pressure via a side
line connection.
All rats received an initial bolus mixture
of 2.4mCi/8.34nmol [U-14C]-glucose, 4.8mCi/
268pmol [3H]-2-DG and antipyrine in saline fol-
lowed by a constant infusion rate of 0.036ml/min
10min prior to and during the collection of pla-
cental perfusion effluent, termed the perfusate.
The infusion mixture consisted of 1.2mCi/
4.17nmol [U-14C]-glucose and 2.4mCi/134pmol
[3H]-2-DG in antipyrine-saline solution.
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Placental Perfusion In Situ
Once the neck vessels were cannulated and
infusion commenced a laparotomy was per-
formed, a fetus was exteriorised to expose the
umbilical vein and artery that were then cannu-
lated prior to the removal of the fetus. The
placenta was perfused via the artery at a rate
Of 0.5ml/min for 30min, during which 10 three-
minute (1.5ml) perfusate fractions were col-
lected from the umbilical vein into chilled
pre-weighed tubes. The perfusion fluid consist-
ed of Krebs-Ringer bicarbonate buffer (pH
7.4) supplemented with 30mg/L Dextran 40
and 5g/L bovine serum albumin. D-glucose
(5mmol/1 for control, 20mmol/1 for diabetic
animals) and D-lactate (10mmol/1 for both con-
trol and diabetic animals) were added to the
perfusion fluid to mimic fetal glucose and lac-
tate levels (see Tab. II). A measure of a satis-
factory experiment was that 96-100% of the
inflowing perfusion fluid was recovered after a
single passage through the placenta and that
the adjacent fettlses were alive until removed
from their respective placentae.
Maternal and Fetal Blood Sampling
During the 30 minute perfusate collection, 6
maternal blood samples (0.6ml) were taken at
6min intervals and divided equally between
chilled pre-weighed heparinized test tubes and
those containing 10% perchloric acid. At the
end of the experiment, the remaining fetuses
in utero were sequentially removed. Fetal
blood samples were obtained from cut axillary
vessels with a heparinized Pasteur pipette and
the samples from each litter pooled. A final
maternal blood sample was then taken. All
plasma samples were aliquoted prior to stor-
age at -20 C.
Analysis of Samples
Deproteinated samples were kept at -70C for
total lactate and [14C]-lactate determinations.
These samples were neutralized with 1M KOH
prior to analysis. Total lactate determinations
were carried out by the method of Engel and
Jones. [151 [14C]-lactate was separated from the
[14C]-glucose by a modified method described
by Moran et al. [16] using microcolumns (0.5cm
3cm) of ion exchange resins AG 50W 8X (cation-
ic) and AG 1 8 (anionic) in tandem. Recoveries
for [14C]-glucose, [3H]-2-deoxyglucose and
[14C]-lactate from these microcolumns were
between 95-98%. Optiphase Hisafe 3 scintilla-
tion fluid was added to the collected eluates
and counted for /3-emission in a dual channel
programme on the LKB 1219 Rackbeta Spectral
liquid scintillation counter. Quencing and spill-
over of the high-energy isotope counts into the
low-energy counting channel were determined
and corrected for by the channel ratio method,
using an external standard and two "curves" of
CC14-quenched [3H] and [14C]n-hexadecane
standards.
Maternal and fetal plasma and perfusate
were analysed for glucose using the glucose
oxidase method (YSI 23 AM analyser, Yellow
Springs, OH, USA). Antipyrine was measured
in all maternal and perfusate samples by the
method of Brodie et al. [17] Insulin measure-
ments on maternal and fetal plasma was by
an in house radioimmunoassay[18] using an
insulin antibody raised in guinea pigs and a
rat insulin standard. 2-deoxyglucose-6-phos-
phate (2DG6P) levels were determined in
fetal and placental tissues by the method of
Ferre et al. [19]
Calculations
Maternal (M) to perfusate (P) transfer was calcu-
lated as the individual ratios of counts in the per-
fustae (dpm/ml) to that in the maternal plasma
(dpm/ml). The values were first averaged from
each rat. A grand mean for each group was then
calculated. Glucose uptake for fetal and placental
tissues were estimated using the glucose meta-
bolic index (GMI) calculated based on the ratio of
the concentration of [3H]-2DG-6-P within the
tissues to the integral of the ratio between
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[3H]-2DG to maternal glucose concentration with
time, i.e.,
GMI [DG-6-P] .dt [Maternal DG]/30[Maternal glucose]
Statistical significance was tested using Student
t-test between variables of the two groups.
Values were expressed as means+standard
error of the mean. The specific activities were
different for the control and diabetic animals,
these are negated by expressing values as per-
fusate over maternal ratios (P/M).
RESULTS
Maternal weight, litter size and fetal weight were
significantly reduced in the diabetic rats com-
pared with normal rats. The converse was seen
with the placentae in the two groups (Tab. I).
The administered dose of streptozotocin in-
creased maternal glycaemia 5 fold (Tab. II) and
decreased the maternal plasma level of insulin by
64% (Tab. II). Fetal glucose concentrations in the
diabetic group were similarly elevated, however
the decrease in fetal plasma insulin level was only
38%. Maternal plasma lactate concentrations were
similar in the two groups. Fetal plasma lactate
concentrations were significantly higher in the
diabetic animals compared with the controls but
more striking was the difference in concentration
between the maternal and fetal levels in both dia-
betic and control animals (Tab. II). The placentae
were perfused with 10mmol/1 lactate and the per-
fusate lactate concentation was estimated in each
perfusate aliquot. There was a non significant net
production of 0.88 0.37mol/minute for the
control animals and a non significant net uptake of
0.33 +0.34mol/minute in the diabetic animals.
These values were not significantly different from
each other. Fetal blood was collected at the end of
the experiment from the remaining fetuses when
the blood flow to the placenta may have been
compromised, possibly resulting in fetal hypoxia
and elevating the lactate concentration further.
Antipyrine, a diffusable marker, was used as an
indirect measure of maternal placental blood flow.
The placental transfer of antipyrine, glucose and
lactate was expressed as a ratio of that in the per-
fusate to that in the simultaneous maternal plasma
sample (P:M), (Tab. III). The antipyrine ratio was
reduced to 59% in the diabetic group compared to
the control group, indicating a decrease in uterine
blood flow in the former. The mean P:M transfer
ratio of [14C]-glucose, [14C]-lactate and [3H]-2-DG
within the groups were similar but all were sub-
stantially reduced in the diabetic group compared
TABLE Litter size, maternal, fetal and placental weights
Control (n 10) Diabetic (n 10) p value
Litter size 14.69 0.58 12.73 0.67 0.05
Maternal Weight (g) 391.53 4.25 343.18 8.64 0.0001
Placental Weight (g) 0.53 0.02 0.64 +_ 0.03 0.01
Fetal Weight (g) 3.97 + 0.17 3.36 0.19 0.05
TABLE II Glucose, lactate and insulin plasma concentrations of control (n 10) and diabetic
(n= 10) dams and their fetuses
Control (n 10) Diabetic (n 10) p value
Maternal Plasma Glucose (mmol/1)
Fetal Plasma Glucose (mmol/1)
Maternal Plasma Lactate (mmol/1)
Fetal Plasma Lactate (mmol/1)
Maternal Insulin (mU/1)
Fetal Insulin (mU/1)
5.1 0.5 25.3 2.0 0.0000
4.4 +___ .6 17.1 1.1 0.0001
3.1 0.5 2.9 + 0.4 NS
13.3 +__ 1.3 18.8 +__ 1.5 0.005
69.5 + 8.5 24.4 5.6 0.005
43.7 +__ 3.2 29.8 3.7 0.01
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TABLE III Placental transfer of [14C]-glucose, [3H]-2-Deoxyglucose 2,
[14C]-lactate and antipyrine in control (n 10) and diabetic (n 10) dams.
The transfer ratios are expressed as the radioactivity in the perfusate (P) to
the radioactivity in the simultaneous maternal (M) samples
Control (P’M) Diabetic (P’M) p value
[3H]-2-Deoxyglucose 0.433 +0.027 0.183 0.015 0.0001
[14C] Glucose 0.407 0.024 0.212 0.04 0.005
[14C] Lactate 0.477 0.048 0.163 0.018 0.0001
Antipyrine 0.498 0.068 0.293 0.024 0.01
TABLE IV Fetal to maternal plasma ratios of [14C]-glucose, [3H]-2-Deoxy-
glucose and [14C]-lactate, determined from the pooled fetal plasma at the end
of each experiment
Control (F’M) Diabetic (F’M) p value
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FIGURE 1 2-Deoxyglucose-6-phosphate uptake per 100 grams wet weight in control and diabetic placentas and fetal carcasses.
with values of the control group. When the [3H]-2-
DG, [U14C]-glucose and [14C]-lactate P:M ratios
in the diabetic model were corrected for the
decrease in antipyrine ratio, the values were 0.310,
0.359, and 0.276 respectively. These values were all
lower than the respective control values (Tab. III).
Thus the decrease in transfer of the three tracers
could not be entirely accounted for by the decrease
in the antipyrine ratio.
The transferred [U14C]-glucose, [3H]-2-DG
and [14C]-lactate in the adjacent fetuses were
also monitored (Tab. IV) and expressed as the
fetal to maternal plasma (F :M) ratios. In fetal
plasma [3H]-2-DG and [14C]-lactate F :M ratios
were similar between the two groups. How-
ever, the F:M ratio of [U14C]-glucose in the
diabetic group was two fold higher compared
with controls.
















The calculated glucose metabolic index of control and diabetic placentas and fetal carcasses lactate.
The quantity of [3H]-2-DG-6-P present in the
placentae, whole fetuses and fetal livers of
diabetic group was significantly less compared
with the controls group (p K0.05, p<0.0005,
p 0.0005, respectively; Fig. 1). However, when
the GMI was calculated fetal uptake of glucose
was not significantly different between control
and diabetic animals. The calculated GMI for
the fetal livers and placentas were significantly
increased in diabetic group compared with the
controls (Fig. 2).
DISCUSSION
The main finding in this rat model was that the
elevated fetal lactate concentrations observed in
control and diabetic animals were not derived
from the placenta, as there was no significant
uptake or secretion of lactate from or into the per-
fusion medium. This was a somewhat unexpected
finding. In vivo sheep experiments have shown
that in mid gestation there is no secretion of lac-
tate by the placenta to the fetal circulation, but at
term lactate secretion to the fetus is substan-
tial. [7,11] In our model we only examined placental
lactate production and transfer to the fetal com-
partment. Aldoretta and Hay[2] have examined
lactate production derived from glucose in late
gestation in sheep under hypoglycaemic and
hyperglycaemic states. Less lactate derived from
glucose was secreted into the fetus in the hyper-
glycaemic than in the hypoglycaemic sheep. This
may be due to the higher fetal plasma lactate con-
centration observed in the hyperglycaemic sheep,
since direction of lactate transport is determined
by the transmembrane lactate concentration. [21]
The lactate concentration in the medium perfus-
ing the fetal side of the placenta in our experi-
ments was 10mmol/1 considerably higher than
the maternal concentration. This gradient effect
may also account for lactate secretion when pla-
cental slices are incubated without added lactate
in the incubating medium. [22] Approximately 40%
of ovine fetal lactate is not derived from glu-
cose and alanine is the likeliest source. The pro-
duction of [14C] lactate from L-[14C] alanine has
been examined by Palcin et al. [22] in pregnant
Wistar rats. In their in vivo experiments significant
quantities of both L-[14C] alanine and [14C] lactate
were present in fetal plasma following the infu-
sion of L-[4C] alanine into an external maternal
iliac artery. Deamination of the L-[14C] alanine
may have occurred in either the fetus or the pla-
centa. Fetal plasma lactate levels were 15mmol/1
in their experiments similar to the values in our
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fetuses adjacent to the perfused placenta. Signifi-
cant quantities of fetal lactate may thus be derived
from fetal rather than from placental alanine
deamination. Glycogen levels have been shown to
be increased in the diabetic rodent placenta. [13]
Lactate production from placental glycogen syn-
thesised from infused universally labelled glucose
during the 30-minute experiment would have
caused a gradual rise in the P:M [14C]-lactate
ratio. However, this was not ob-served. The ob-
served placental secretion patterns in different
models and at different gestational ages would
suggest that there is a control mechanism deter-
mining lactate secretion to the fetal and or mater-
nal circulation. Lactate is a universal alternative
substrate to glucose for tissues including the
brain. [23,24] Thus maintaining the plasma fetal lac-
tate level above the maternal concentration may
provide an alternative fetal nutrient.
The observed elevated fetal lactate levels of the
diabetic dams compared with controls were not
due to maternal to fetal placental transfer since the
P:M [14C]-lactate ratio, together with the P:M
ratio of [U4C]-glucose and [3H]-2-DG, were sig-
nificantly lower compared with control animals.
Additionally the total maternal plasma lactate lev-
els were similar in the two groups. In this model
the elevated fetal lactate values in either group
have not been shown to be of placental origin.
The documented presence of very low enzyme
activities of the citric-acid-cycle [25] in fetal hepa-
tocytes may account for the presence of elevated
fetal lactate concentrations compared with the
mother. The significantly higher fetal lactate lev-
els in the presence of maternal diabetes were
probably secondary to reduced fetal insulin lev-
els. The combination of the reduced P:M ratio of
[U4C]-glucose, and a higher F:M ratio in diabet-
ic compared with control animals, suggests that
against the background of maternal hypergly-
caemia there was reduced fetal glucose uptake.
This is supported by the lower deposition of 2-
[3H]-DG-6-P observed in the fetuses and placen-
tas of diabetic dams. Despite this decrease in
2-[3H]-DG-6-P deposition, total glucose uptake
from calculated GMI was increased in the pla-
centa. The higher F:M ratio of the specific
activities of glucose in the maternal and fetal
circulation in the diabetic group (0.86_+0.05)
compared with controls (0.41 _+ 0.03) suggests that
the fetuses of the diabetic dams were only able to
achieve glucose uptake similar to the control
fetuses at hyperglycaemic glucose concentrations.
The GMI of the whole fetus in the two groups
were similar although fetal liver GMI, an insulin
independent tissue, was increased. This could be
a protective mechanism whereby the redu’ced
fetal plasma insulin levels limits glucose metabo-
lism in insulin sensitive tissues and prevents
excessive somatic growth. This is supported by
the observation of reduced fetal myocardial and
skeletal muscle insulin sensitive Glut-4 trans-
porter expression in chronically hyperglycaemic
sheep. [26] Fetal insulin synthesis would not have
been affected by streptozotocin as the drug was
administered to the mother prior to the implanta-
tion of the conceptus (day 5). Reduced fetal
insulin secretion in the diabetic group may, there-
fore, be a direct result of glucotoxicity, a phenom-
enon also observed in sheep with chronically
elevated maternal plasma glucose levels. [27]
The observed increased diabetic placental
glucose uptake is in agreement with Thomas
and Lowy [28] but differed in magnitude. This
may be related to two factors, the rats in this
study were only moderately diabetic compared
with the previous study, and they were main-
tained on a diet optimal for breeding which had
been enriched in protein (20.5%w/w) compared
to the standard diet used in the previous study.
CONCLUSION
Placental glucose transport is less efficient in dia-
betic animals, but is compensated for by the five-
fold higher maternal glucose concentration,
resulting in an increased delivery of glucose to
the fetal compartment. [3H]-2DG-6-P deposition
was significantly reduced in fetuses of diabetic
dams. As the result of the five-fold higher fetal
plasma glucose concentration in the diabetic
model, the total fetal carcass glucose uptake, as
calculated by GMI, was similar in the 2 groups.
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This relatively reduced fetal glucose uptake
may be due to the low insulin levels in the dia-
betic animals. The P:M ratios observed for
tracer lactate, glucose and 2-deoxyglucose indicate
that the placenta will transport lactate. However,
the placenta did not secrete significant quantities
of lactate in this experimental model. The ele-
vated fetal lactate concentrations are therefore
a" primary product of fetal metabolism. This
metabolic pathway is enhanced in the diabetic
animal resulting in higher plasma fetal lactate
levels.
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